AIDS is a global public health problem, a chronic, potentially life-threatening disease caused by the human immunodeficiency virus (HIV). Because HIV mutates rapidly into new strains, developing a vaccine is difficult. An experimental HIV vaccine produced antibodies in 97 percent of participants, according to a study published in the journal Science. Of 36 trial participants who received two doses of the HIV vaccine 8 weeks apart, 35 developed antibodies to the virus and no serious side effects were noted. The vaccine, called eOD-GT8 60mer, stimulates B cells to produce HIV-specific broadly neutralizing antibodies. Of all participants, 98 percent experienced minor side effects such as fatigue, headache and pain at the injection site. In most cases, these side effects get better within a day or two.
This article is transferred from: https://www.solidot.org/story?sid=73558
This site is only for collection, and the copyright belongs to the original author.